Molecular Targeted Approaches for Advanced <i>BRAF</i> V600, <i>N-RAS</i>, <i>c-KIT</i>, and <i>GNAQ</i> Melanomas

<table>Clinical features of patients treated with <i>BRAF</i> inhibitors.</table>

Disease Markers

Figure 1: Molecular Targeted Approaches for Advanced <i>BRAF</i> V600, <i>N-RAS</i>, <i>c-KIT</i>, and <i>GNAQ</i> Melanomas 